BR112014011028A2 - molécula de ligação isolada ou fragmento de ligação de antígeno da mesma, anticorpo biespecífico, molécula de polinucleotídeo isolada, composição, método para a prevenção ou tratamento de uma infecção por pseudomonas em um indivíduo, e, kit - Google Patents
molécula de ligação isolada ou fragmento de ligação de antígeno da mesma, anticorpo biespecífico, molécula de polinucleotídeo isolada, composição, método para a prevenção ou tratamento de uma infecção por pseudomonas em um indivíduo, e, kitInfo
- Publication number
- BR112014011028A2 BR112014011028A2 BR112014011028A BR112014011028A BR112014011028A2 BR 112014011028 A2 BR112014011028 A2 BR 112014011028A2 BR 112014011028 A BR112014011028 A BR 112014011028A BR 112014011028 A BR112014011028 A BR 112014011028A BR 112014011028 A2 BR112014011028 A2 BR 112014011028A2
- Authority
- BR
- Brazil
- Prior art keywords
- isolated
- molecule
- kit
- treating
- preventing
- Prior art date
Links
- 208000032536 Pseudomonas Infections Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161556645P | 2011-11-07 | 2011-11-07 | |
US61/556,645 | 2011-11-07 | ||
US201261625299P | 2012-04-17 | 2012-04-17 | |
US61/625,299 | 2012-04-17 | ||
US201261697585P | 2012-09-06 | 2012-09-06 | |
US61/697,585 | 2012-09-06 | ||
PCT/US2012/063722 WO2013070615A1 (en) | 2011-11-07 | 2012-11-06 | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014011028A2 true BR112014011028A2 (pt) | 2017-05-02 |
BR112014011028B1 BR112014011028B1 (pt) | 2021-03-02 |
Family
ID=48290482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014011028-0A BR112014011028B1 (pt) | 2011-11-07 | 2012-11-06 | anticorpo biespecífico, composição, e, uso da composição |
Country Status (22)
Country | Link |
---|---|
US (3) | US10597439B2 (pt) |
EP (1) | EP2776065B1 (pt) |
JP (1) | JP6182152B2 (pt) |
KR (1) | KR102184343B1 (pt) |
CN (1) | CN104136042B (pt) |
AU (3) | AU2012336028A1 (pt) |
BR (1) | BR112014011028B1 (pt) |
CA (2) | CA2854817C (pt) |
CY (1) | CY1123552T1 (pt) |
DK (1) | DK2776065T3 (pt) |
ES (1) | ES2859323T3 (pt) |
HK (1) | HK1201453A1 (pt) |
HR (1) | HRP20201370T1 (pt) |
HU (1) | HUE050985T2 (pt) |
LT (1) | LT2776065T (pt) |
MX (1) | MX2014005566A (pt) |
PL (1) | PL2776065T3 (pt) |
PT (1) | PT2776065T (pt) |
RS (1) | RS60920B1 (pt) |
RU (1) | RU2687588C2 (pt) |
SI (1) | SI2776065T1 (pt) |
WO (1) | WO2013070615A1 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6058645B2 (ja) | 2011-06-10 | 2017-01-11 | メディミューン,エルエルシー | 抗シュードモナス属(Pseudomonas)Psl結合分子およびその使用 |
CA2854817C (en) * | 2011-11-07 | 2022-08-16 | Medimmune, Llc | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
CN104144945A (zh) * | 2012-03-02 | 2014-11-12 | 埃博灵克斯股份有限公司 | 结合铜绿假单胞菌pcrv的单可变结构域抗体 |
US20150284450A1 (en) * | 2012-11-06 | 2015-10-08 | Medimmune, Llc | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
AU2014265632B2 (en) | 2013-05-14 | 2019-09-19 | Medimmune, Llc | Synthetic oligosaccharide subunits of the psl exopolysaccharide of pseudomonas aeruginosa and uses thereof |
WO2015171504A1 (en) * | 2014-05-05 | 2015-11-12 | Medimmune, Llc | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
TWI719938B (zh) * | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
JP6966330B2 (ja) | 2015-05-01 | 2021-11-17 | インヒブルクス,インコーポレイティド | Iii型分泌装置標的化分子 |
JP2018527924A (ja) * | 2015-08-24 | 2018-09-27 | メディミューン,エルエルシー | Mrkaポリペプチド、抗体、およびその使用 |
SG11201803794YA (en) * | 2015-11-30 | 2018-06-28 | Medimmune Ltd | Method for preventing or treating nosocomial pneumonia |
EA201892525A1 (ru) * | 2016-05-05 | 2019-04-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Конструкции днк-антител для применения против pseudomonas aeruginosa |
MA56205A (fr) | 2019-06-11 | 2022-04-20 | Regeneron Pharma | Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation |
BR112021026788A2 (pt) * | 2019-07-09 | 2022-05-10 | Staidson Beijing Biopharmaceuticals Co Ltd | Anticorpos que reconhecem especificamente pcrv de pseudomonas e usos dos mesmos |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
WO2021244421A1 (en) * | 2020-06-01 | 2021-12-09 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing pseudomonas pcrv and uses thereof |
WO2022028444A1 (en) * | 2020-08-07 | 2022-02-10 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing pseudomonas psl and uses thereof |
FR3114970B1 (fr) * | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
KR20230109703A (ko) * | 2020-11-18 | 2023-07-20 | 베이징 솔로바이오 진테크놀로지 컴퍼니 리미티드 | 슈도모나스 pcrv 및 psl을 특이적으로 식별하는 항체 결합을 포함하는 항체 조합 및 이중특이성 항체 |
WO2023141611A2 (en) * | 2022-01-21 | 2023-07-27 | Lyvgen Biopharma Holdings Limited | Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation |
WO2024003103A1 (en) | 2022-06-29 | 2024-01-04 | Astrazeneca Ab | Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
DE3685700T2 (de) | 1985-03-11 | 1993-03-11 | Teijin Ltd | E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom. |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
US6190370B1 (en) | 1997-07-25 | 2001-02-20 | Arrow International, Inc. | Devices, systems and methods for determining proper placement of epidural catheters |
IL138857A0 (en) | 1998-04-21 | 2001-10-31 | Micromet Ges For Biomedizinisc | Cd19xcd3 specific polypeptides and uses thereof |
ES2255329T3 (es) | 1998-11-25 | 2006-06-16 | Mcw Research Foundation, Inc. | Metodo y composiciones para inmunizacion con el antigeno v de pseudomonas aeruginosa. |
AU2001297872B2 (en) | 2000-11-17 | 2006-11-09 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
ATE347374T1 (de) * | 2001-01-26 | 2006-12-15 | Mcw Res Found Inc | Verfahren und zusammensetzungen für immunisierung mit dem pseudomonas antigen |
US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
US20020146753A1 (en) * | 2001-04-06 | 2002-10-10 | Henrik Ditzel | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease |
US7119172B2 (en) | 2001-05-21 | 2006-10-10 | The Brigham And Women's Hospital, Inc. | P. aeruginosa mucoid exopolysaccharide specific binding peptides |
US20030232387A1 (en) * | 2002-06-14 | 2003-12-18 | Millennium Pharmaceuticals, Inc. | Antibodies that bind alphaE integrin |
US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
BRPI0615026A8 (pt) | 2005-08-19 | 2018-03-06 | Abbott Lab | imunoglobulina de domínio variável duplo e seus usos |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US7790862B2 (en) * | 2006-06-13 | 2010-09-07 | Zymogenetics, Inc. | IL-17 and IL-23 antagonists and methods of using the same |
JP2008133206A (ja) * | 2006-11-28 | 2008-06-12 | Yokohama City Univ | 緑膿菌に対して感染防御能を誘導できる医薬組成物 |
US7553936B2 (en) | 2006-12-04 | 2009-06-30 | The United States of America as represented by Secretary Department of Health and Human Services | Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions |
WO2008074840A2 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
EP2220117A2 (en) | 2007-11-30 | 2010-08-25 | Kalobios Pharmaceuticals, Inc. | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
PT2248826E (pt) * | 2008-01-10 | 2013-09-06 | Shionogi & Co | Anticorpo dirigido contra pcrv |
MX2010007767A (es) | 2008-01-18 | 2010-08-09 | Medimmune Llc | Anticuerpos manipulados con cisteina para conjugacion especifica de sitio. |
US20100172862A1 (en) | 2008-11-28 | 2010-07-08 | Abbott Laboratories | Stable antibody compositions and methods of stabilizing same |
JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
EP2382141B1 (en) * | 2008-12-31 | 2014-11-19 | W.L. Gore & Associates GmbH | Venting device |
CA2751433A1 (en) * | 2009-02-04 | 2010-08-12 | Kalobios Pharmaceuticals, Inc. | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
SG174225A1 (en) * | 2009-03-11 | 2011-10-28 | Shionogi & Co | Humanized pcrv antibody having anti-pseudomonal activity |
EP2408475B1 (en) * | 2009-03-18 | 2017-11-15 | Wake Forest University Health Sciences | Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa |
EP3385279B1 (en) | 2009-03-20 | 2020-02-26 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
MX2011010634A (es) | 2009-04-09 | 2012-03-06 | Kenta Biotech Ag | Anticuerpos monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 01 de pseudomonas aeruginosa. |
EP2711018A1 (en) | 2009-06-22 | 2014-03-26 | MedImmune, LLC | Engineered Fc regions for site-specific conjugation |
EP2515935A4 (en) | 2009-12-22 | 2013-08-28 | Kalobios Pharmaceuticals Inc | METHOD FOR TREATING STAPHYLOCOCCUS INFECTION IN A PATIENT WITH PSEUDOMONAS AERUGINOSA INFECTION WITH LOW PATHOGEN LEVEL |
SG192212A1 (en) * | 2011-02-08 | 2013-09-30 | Medimmune Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
WO2012145626A1 (en) | 2011-04-22 | 2012-10-26 | Ancora Pharmaceuticals Inc. | Synthetic oligosaccharides for staphylococcus vaccine |
JP6058645B2 (ja) * | 2011-06-10 | 2017-01-11 | メディミューン,エルエルシー | 抗シュードモナス属(Pseudomonas)Psl結合分子およびその使用 |
CA2854817C (en) | 2011-11-07 | 2022-08-16 | Medimmune, Llc | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
WO2013070565A1 (en) | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
CN104144945A (zh) * | 2012-03-02 | 2014-11-12 | 埃博灵克斯股份有限公司 | 结合铜绿假单胞菌pcrv的单可变结构域抗体 |
MX2015005477A (es) * | 2012-11-06 | 2015-11-30 | Medimmune Llc | Anticuerpos contra determinantes de la superficie de s. aureus. |
KR20150092738A (ko) * | 2012-11-06 | 2015-08-13 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
US20150284450A1 (en) * | 2012-11-06 | 2015-10-08 | Medimmune, Llc | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
AU2014265632B2 (en) | 2013-05-14 | 2019-09-19 | Medimmune, Llc | Synthetic oligosaccharide subunits of the psl exopolysaccharide of pseudomonas aeruginosa and uses thereof |
WO2015171504A1 (en) * | 2014-05-05 | 2015-11-12 | Medimmune, Llc | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
TWI719938B (zh) * | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
SG11201803794YA (en) * | 2015-11-30 | 2018-06-28 | Medimmune Ltd | Method for preventing or treating nosocomial pneumonia |
EA201892525A1 (ru) * | 2016-05-05 | 2019-04-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Конструкции днк-антител для применения против pseudomonas aeruginosa |
MA56205A (fr) * | 2019-06-11 | 2022-04-20 | Regeneron Pharma | Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation |
-
2012
- 2012-11-06 CA CA2854817A patent/CA2854817C/en active Active
- 2012-11-06 PT PT128474798T patent/PT2776065T/pt unknown
- 2012-11-06 CN CN201280054651.8A patent/CN104136042B/zh active Active
- 2012-11-06 MX MX2014005566A patent/MX2014005566A/es active IP Right Grant
- 2012-11-06 RS RS20201211A patent/RS60920B1/sr unknown
- 2012-11-06 WO PCT/US2012/063722 patent/WO2013070615A1/en active Application Filing
- 2012-11-06 ES ES12847479T patent/ES2859323T3/es active Active
- 2012-11-06 JP JP2014540196A patent/JP6182152B2/ja active Active
- 2012-11-06 SI SI201231834T patent/SI2776065T1/sl unknown
- 2012-11-06 EP EP12847479.8A patent/EP2776065B1/en active Active
- 2012-11-06 RU RU2014122990A patent/RU2687588C2/ru active
- 2012-11-06 US US14/356,500 patent/US10597439B2/en active Active
- 2012-11-06 CA CA3161431A patent/CA3161431A1/en active Pending
- 2012-11-06 KR KR1020147015274A patent/KR102184343B1/ko active IP Right Grant
- 2012-11-06 AU AU2012336028A patent/AU2012336028A1/en not_active Abandoned
- 2012-11-06 HU HUE12847479A patent/HUE050985T2/hu unknown
- 2012-11-06 BR BR112014011028-0A patent/BR112014011028B1/pt active IP Right Grant
- 2012-11-06 PL PL12847479T patent/PL2776065T3/pl unknown
- 2012-11-06 LT LTEP12847479.8T patent/LT2776065T/lt unknown
- 2012-11-06 DK DK12847479.8T patent/DK2776065T3/da active
-
2015
- 2015-02-27 HK HK15101962.5A patent/HK1201453A1/xx unknown
-
2017
- 2017-08-25 AU AU2017219081A patent/AU2017219081B9/en active Active
-
2019
- 2019-09-05 AU AU2019226205A patent/AU2019226205A1/en not_active Abandoned
-
2020
- 2020-02-13 US US16/789,790 patent/US11203633B2/en active Active
- 2020-08-28 HR HRP20201370TT patent/HRP20201370T1/hr unknown
- 2020-10-08 CY CY20201100949T patent/CY1123552T1/el unknown
-
2021
- 2021-11-15 US US17/454,837 patent/US20220177554A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014011028A2 (pt) | molécula de ligação isolada ou fragmento de ligação de antígeno da mesma, anticorpo biespecífico, molécula de polinucleotídeo isolada, composição, método para a prevenção ou tratamento de uma infecção por pseudomonas em um indivíduo, e, kit | |
BR112014002618A2 (pt) | anticorpo ou um fragmento do mesmo, que tem reatividade imunológica com uma proteína caprin-1, composição farmaceutica e combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método para tratamento e/ou prevenção de cãncer | |
BR112012018947A8 (pt) | composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer | |
BR112012003809A2 (pt) | anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo. | |
BR112014002614A2 (pt) | anticorpo ou um fragmento do mesmo, que tem reatividade imunológica com uma proteína caprin-1, composição farmacêutica e combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método para tratamento e/ou prevenção de câncer | |
BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
BR112014002621A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento | |
BR112014000263A2 (pt) | anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico, e, composição farmacêutica | |
BRPI0909627A2 (pt) | métodos, composições e kits para tratar dores e pruridos | |
BRPI0817664A2 (pt) | Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo | |
BRPI0812446A2 (pt) | Métodos para aperfeiçoamento de propriedades de proteína múltiplas | |
BRPI0922122A2 (pt) | composições e métodos para tratamento de doença celíaca. | |
BR112012028530A2 (pt) | composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno | |
BR112013023653A2 (pt) | anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica | |
BRPI0921317A2 (pt) | composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero | |
BR112014002616A2 (pt) | método para detectar cãncer pancreático e reagente ou kit para detectar câncer pancreático | |
BRPI1004899A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac | |
BRPI0918178A2 (pt) | anticorpos monoclonais para tratamento de câncer | |
BRPI0915382A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio. | |
BR112013008957A2 (pt) | composições e métodos para tratamento de doenças endócrinas, gastrointestinais ou autoimunes | |
BR112012004333A2 (pt) | composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio. | |
BRPI0819688A2 (pt) | Processo para tratamento de fratura óssea com anticorpos anti-esclerostina. | |
BRPI0905761A2 (pt) | Anticorpo humanizado ou fragmento de ligação ao mesmo, ácido nucléico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou o fragmento de ligação ao mesmo, composição, método para tratar uma doença ou distúrbio mediado por vwf em um indivíduo, uso de um anticorpo humanizado ou fragmento de ligação do mesmo, método para administração do anticorpo humanizado ou fragmento de ligação do mesmo, artigo de fabricação e kit | |
BR112013019083A2 (pt) | combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença. | |
BR112014010162A8 (pt) | uso de composição, método para melhorar o reconhecimento e/ou tratar ou prevenir função de reconhecimento prejudicada em um indivíduo, e composição |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/11/2012, OBSERVADAS AS CONDICOES LEGAIS. |